-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, Mindray Medical released its 2021 annual report
.
The annual report shows that last year, the company achieved operating income of 25.
270 billion yuan, a year-on-year increase of 20.
18%; net profit attributable to the parent was 8.
002 billion yuan, a year-on-year increase of 20.
19%, and the net cash flow generated by operating activities reached 8.
999 billion yuan.
Shares distribute cash dividends of 35 yuan
.
On the same day, Mindray Medical also released its first quarterly report for 2022
.
In the first quarter, the company achieved operating income of 6.
943 billion yuan, a year-on-year increase of 20.
10%; net profit attributable to the parent was 2.
105 billion yuan, a year-on-year increase of 22.
74%
.
Mindray Medical said that the profit growth rate was faster than the revenue mainly due to the continuous and stable growth of the company's operating income, which brought the continuous reflection of the scale effect, so the net profit margin was optimized
.
On the whole, Mindray Medical has obvious competitive advantages in R&D, production, marketing, etc.
Its main business covers three major fields of life information and support, in vitro diagnosis, and medical imaging, which maintain a good growth trend.
The smart medical field has also accelerated its layout
.
In addition, Mindray Medical also took advantage of the overseas market opportunities brought about by the epidemic.
During the reporting period, the company's overseas business developed rapidly, and the high-end customer base was further expanded both vertically and horizontally
.
It is worth noting that, as a R&D and manufacturer of high-tech medical equipment, the high R&D investment in the field of product technology innovation is the foundation of Mindray Medical
.
In recent years, it has maintained high investment in research and development
.
The first quarterly report of 2022 shows that in the first quarter of this year, Mindray Medical’s investment in research and development reached 742 million yuan, accounting for 10.
69% of the operating income during the reporting period
.
At present, in addition to Mindray Medical, there are actually many medical companies that have also announced their first-quarter results.
On the whole, many companies have seen high growth in performance
.
For example, Wantai Bio, which specializes in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines, recently released a quarterly report showing that in 2022Q1, the company achieved revenue of 3.
171 billion yuan (+284.
85%) and net profit attributable to the parent of 1.
331 billion yuan (+360.
18%).
), deducting non-returnable net profit of 1.
315 billion yuan (+367.
75%)
.
In 2022Q1, the company's revenue and profit have achieved rapid growth, mainly due to the contribution of bivalent HPV vaccines, reagents and active raw materials
.
After that, Weili Medical also announced the first quarterly report of 2022.
The announcement showed that the company's main income was 301 million yuan, a year-on-year increase of 36.
85%; the net profit attributable to the parent was 38.
6127 million yuan, a year-on-year increase of 70.
1%; the deducted non-net profit was 34.
7162 million yuan , a year-on-year increase of 75.
15%
.
In addition, Steady Medical also released its 2021 annual report and 2022 first quarter report
.
In 2021, the company will achieve operating income of 8.
037 billion yuan, net profit attributable to shareholders of the listed company of 1.
239 billion yuan, and basic earnings per share of 2.
91 yuan per share
.
In the first quarter of 2022, the company has achieved operating income of 2.
322 billion yuan and a net profit of 357 million yuan attributable to shareholders of listed companies
.
In addition, according to the 2021 annual performance report released by Jiu'an Medical on April 12, it is expected that the net profit attributable to shareholders of listed companies in the first quarter of 2022 will reach 14 billion yuan to 16 billion yuan, a year-on-year increase of 36707.
43% to 41965.
63%
.
It is understood that the reason for the rapid growth of Jiu'an Medical's performance in the first quarter is mainly due to the impact of the development of the epidemic in the United States, and the local demand for antigen detection kit products has increased significantly
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The annual report shows that last year, the company achieved operating income of 25.
270 billion yuan, a year-on-year increase of 20.
18%; net profit attributable to the parent was 8.
002 billion yuan, a year-on-year increase of 20.
19%, and the net cash flow generated by operating activities reached 8.
999 billion yuan.
Shares distribute cash dividends of 35 yuan
.
On the same day, Mindray Medical also released its first quarterly report for 2022
.
In the first quarter, the company achieved operating income of 6.
943 billion yuan, a year-on-year increase of 20.
10%; net profit attributable to the parent was 2.
105 billion yuan, a year-on-year increase of 22.
74%
.
Mindray Medical said that the profit growth rate was faster than the revenue mainly due to the continuous and stable growth of the company's operating income, which brought the continuous reflection of the scale effect, so the net profit margin was optimized
.
On the whole, Mindray Medical has obvious competitive advantages in R&D, production, marketing, etc.
Its main business covers three major fields of life information and support, in vitro diagnosis, and medical imaging, which maintain a good growth trend.
The smart medical field has also accelerated its layout
.
In addition, Mindray Medical also took advantage of the overseas market opportunities brought about by the epidemic.
During the reporting period, the company's overseas business developed rapidly, and the high-end customer base was further expanded both vertically and horizontally
.
It is worth noting that, as a R&D and manufacturer of high-tech medical equipment, the high R&D investment in the field of product technology innovation is the foundation of Mindray Medical
.
In recent years, it has maintained high investment in research and development
.
The first quarterly report of 2022 shows that in the first quarter of this year, Mindray Medical’s investment in research and development reached 742 million yuan, accounting for 10.
69% of the operating income during the reporting period
.
At present, in addition to Mindray Medical, there are actually many medical companies that have also announced their first-quarter results.
On the whole, many companies have seen high growth in performance
.
For example, Wantai Bio, which specializes in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines, recently released a quarterly report showing that in 2022Q1, the company achieved revenue of 3.
171 billion yuan (+284.
85%) and net profit attributable to the parent of 1.
331 billion yuan (+360.
18%).
), deducting non-returnable net profit of 1.
315 billion yuan (+367.
75%)
.
In 2022Q1, the company's revenue and profit have achieved rapid growth, mainly due to the contribution of bivalent HPV vaccines, reagents and active raw materials
.
After that, Weili Medical also announced the first quarterly report of 2022.
The announcement showed that the company's main income was 301 million yuan, a year-on-year increase of 36.
85%; the net profit attributable to the parent was 38.
6127 million yuan, a year-on-year increase of 70.
1%; the deducted non-net profit was 34.
7162 million yuan , a year-on-year increase of 75.
15%
.
In addition, Steady Medical also released its 2021 annual report and 2022 first quarter report
.
In 2021, the company will achieve operating income of 8.
037 billion yuan, net profit attributable to shareholders of the listed company of 1.
239 billion yuan, and basic earnings per share of 2.
91 yuan per share
.
In the first quarter of 2022, the company has achieved operating income of 2.
322 billion yuan and a net profit of 357 million yuan attributable to shareholders of listed companies
.
In addition, according to the 2021 annual performance report released by Jiu'an Medical on April 12, it is expected that the net profit attributable to shareholders of listed companies in the first quarter of 2022 will reach 14 billion yuan to 16 billion yuan, a year-on-year increase of 36707.
43% to 41965.
63%
.
It is understood that the reason for the rapid growth of Jiu'an Medical's performance in the first quarter is mainly due to the impact of the development of the epidemic in the United States, and the local demand for antigen detection kit products has increased significantly
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
